Personalized outreach and multifaceted interventions for screening enhancement (PROMISE) for anal and cervical cancer prevention and treatment - in the US, anal cancer (AC) and cervical cancer (CC)…

Active Cooperative Agreement Awarded Last action

Award ID
U54CA302465
Recipient
Awarding agency
Obligated
$4,672,458

Award facts

Assistance listing
93.397 Cancer Centers Support Grants
Completion date 24% complete
Originally
Place of performance
Florida, USA

Award details come from USAspending.gov.

Description

Personalized outreach and multifaceted interventions for screening enhancement (PROMISE) for anal and cervical cancer prevention and treatment - in the US, anal cancer (AC) and cervical cancer (CC) disproportionately affect the most vulnerable-those who must navigate complex, cumulative intersectionality that further constrains access to disease prevention. In south florida and georgia, the catchment areas for the SYLVESTER comprehensive cancer center (SYLVESTER), and WINSHIP cancer institute (WINSHIP), AC and CC incidence remains high among blacks and hispanics of a variety of ancestries, particularly those in groups at high risk of poor outcome. The proposed personalized outreach and multifaceted interventions for screening enhancement (PROMISE) for anal and cervical cancer prevention and treatment spore will address differences in cancer incidence and outcome across different population groups by leveraging, via horizontal and vertical engagement, the robust infrastructure and capacity of three, top-tier research institutions, with an established history of collaboration. SYLVESTER, WINSHIP, and morehouse school of medicine, individually and collectively, have been at the forefront of high-impact, translational science in AC and CC through validating screening modalities that circumvent multilevel impediments to disease prevention and early detection, as well as examining critical heterogeneity in disease etiology, onset, and progression. PROMISE will expand upon this work via three innovative, high-impact research projects, as well as pilot studies that seek to understand and/or address observed variability in disease outcomes across the cancer control continuum through our developmental research program (DRP). Our commitment to community-engaged, translational science will inform the proposed activities of our career enhancement program (CEP). All projects and programs will leverage the shared expertise of three proposed cores: the community outreach and engagement core (COE), biospecimen and pathology core, and biostatistics and bioinformatics core. PROMISE partners are committed to 1) translating lessons learned from our work in AC and CC into a framework that addresses differences in cancer outcomes; and, 2) deepening the longstanding connections between our academic and community partners to meaningfully modify the landscape of anal and cervical cancer prevention, early detection, diagnosis, and treatment.

Transactions

Action Obligated Date
Amendment $0
Amendment $2,336,229
Original award $2,336,229

Subawards

Subrecipient Amount Awarded
Emory University AWD-010934: FP00015244 U54 SPORE PROMISE_Due:09/26/2024 09/05/2025 (version 0) $74,949
The Morehouse School Of Medicine, Inc. $31,466

Quick answers

Who received award U54CA302465?

U54CA302465 was awarded to University Of Miami by National Cancer Institute (National Institutes of Health) on September 5, 2025.

How much is award U54CA302465 worth?

$4,672,458 has been obligated on U54CA302465.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award